MedPath

Arsenic trioxide

Generic Name
Arsenic trioxide
Brand Names
Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
Drug Type
Small Molecule
Chemical Formula
As2O3
CAS Number
1327-53-3
Unique Ingredient Identifier
S7V92P67HO
Background

Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Indication

For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions
Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Clinical Trials
Related News

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
First Posted Date
2005-09-19
Last Posted Date
2009-01-23
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
40
Registration Number
NCT00193544

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
First Posted Date
2005-09-19
Last Posted Date
2017-03-03
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
87
Registration Number
NCT00195104
Locations
🇺🇸

Weill Medcial College of Cornell University, New York, New York, United States

Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma

Phase 1
Completed
Conditions
Brain Cancer
First Posted Date
2005-09-16
Last Posted Date
2009-04-09
Lead Sponsor
Stanford University
Target Recruit Count
12
Registration Number
NCT00185861
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

Phase 2
Terminated
Conditions
Acute Myelogenous Leukemia
Interventions
First Posted Date
2005-09-16
Last Posted Date
2014-07-25
Lead Sponsor
University of Southern California
Target Recruit Count
11
Registration Number
NCT00184054
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Phase 2
Completed
Conditions
Liver Cancer
First Posted Date
2005-08-10
Last Posted Date
2017-04-27
Lead Sponsor
University of Pittsburgh
Target Recruit Count
25
Registration Number
NCT00128596
Locations
🇺🇸

UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

Phase 1
Completed
Conditions
Refractory Multiple Myeloma
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2005-07-28
Last Posted Date
2013-01-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00124605
Locations
🇺🇸

City of Hope, Duarte, California, United States

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2
Terminated
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2005-07-11
Last Posted Date
2018-05-11
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
1
Registration Number
NCT00118196
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2
Withdrawn
Conditions
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Plasma Cell Neoplasm
First Posted Date
2005-06-03
Last Posted Date
2013-07-10
Lead Sponsor
The Cleveland Clinic
Registration Number
NCT00112879
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Phase 2
Terminated
Conditions
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
First Posted Date
2005-03-04
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
5
Registration Number
NCT00104806
Locations
🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-11-09
Last Posted Date
2011-04-22
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
36
Registration Number
NCT00095771
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy